







New Board Members and P. Thomas employment agreement


UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549




FORM
8-K




CURRENT
REPORT

PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934





Date
of
Report (Date of earliest event reported): December 12, 2007




IMPLANT
SCIENCES CORPORATION




(Exact
Name of Registrant as Specified in Charter)





Massachusetts



000-25839



04-2837126




(State
or other jurisdiction

of
incorporation)


(Commission

File
Number)


(IRS
Employer

Identification
No.)














107
Audubon Road #5

Wakefield,
MA



01880




(Address
of principal executive offices)


(Zip
Code)









Registrant's
telephone number, including area code
(781)
246-0700



Not
Applicable


(Former
Name or Former Address, if Changed Since Last Report)



Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation to the registrant under any of the following
provisions:







□


Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)












□


Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)












□


Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))












□


Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))





















































ITEM
5.02   DEPARTURES OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF
DIRECTIORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENT OF CERTAIN
OFFICERS



On
December 12, 2007, at the Annual Meeting of Implant Sciences Corporation (the
“Company”), the shareholders elected Mr. Phillip Thomas and Mr. Joseph Levangie
to the board of directors. The shareholders also re-elected Dr. Michael Szycher,
Mr. David Eisenhaure and Mr. Michael Turmelle. All five were nominated by the
Company’s Board of Directors. Mr. Thomas currently serves as the Company’s
President, Chief Executive Officer and has been appointed as Chairman of the
Board. Mr. Levangie has been appointed by the board to serve as Chairman of
the
Audit Committee. The board has determined that Mr. Levangie is an audit
committee financial expert as that term is defined in Item 401 of Regulation
S-K
and that he is "independent" as that term is defined in Section 301 of the
Sarbanes-Oxley Act of 2002 and Rule 10A-3(b)(1) of the Securities Exchange
Act
of 1934, as amended.



In
addition, on December 12, 2007, the board of directors approved the the
Employment Agreement (the “Agreement”) of Mr. Thomas, a copy of which is
attached hereto as Exhibit 99.1. The Agreement, having an initial term of three
years, provides for an annual base salary of $275,000, the issuance of 280,000
stock options, an annual incentive bonus program and a car allowance. In
addition, under specific conditions, Mr. Thomas would be eligible for 12 months
severance pay. Non-compete and non-solicitation restrictions apply.













ITEM
9.01 FINANCIAL STATEMENTS AND EXHIBITS




(d)
Exhibits







99.1
Employment
Agreement between Phillip Thomas and Implant Sciences dated September
27,
2007.













































SIGNATURES




Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.



December
14, 2007                                                            IMPLANT
SCIENCES CORPORATION



By:
/s/ Phillip C. Thomas


Phillip
C.
Thomas


President
and CEO





